Literature DB >> 28282274

Improving the Management of Patients With Low-Risk Neutropenic Fever at the Cleveland Clinic Taussig Cancer Institute.

Lindsey Martin Goodman1, Bassam Estfan1, Alberto Montero1, Girish Kunapareddy1, Jessica Lau1, Erika Gallagher1, Carolyn Best1, Barb Tripp1, Machelle Moeller1, Brian Bolwell1, James Stevenson1.   

Abstract

PURPOSE: Neutropenic fever (NF) is an oncologic emergency and has resulted historically in inpatient management. The Multinational Association for Supportive Care in Cancer (MASCC) score can be used to identify patients with NF at a low risk of complications who can be managed safely as outpatients. Despite established guidelines supporting outpatient management of low-risk neutropenic fever (LRNF), provider awareness is low, and inpatient admission for intravenous antibiotics continues to be standard of care.
METHODS: Inpatient provider algorithm implementation and education began in the second quarter of 2014. Providers calculated MASCC scores for patients with nonleukemia hematologic malignancies and solid tumors at admission. Data were collected in a prospectively maintained registry. Patients identified as low risk by MASCC score were placed under observation and started on oral antibiotics. If exclusion criteria and social barriers were not identified, discharge within 48 hours was planned.
RESULTS: Eighty-three patients with NF were admitted to the Taussig Cancer Institute inpatient oncology unit between November 2014 and June 2015. Fifty-three patients (64%) had LRNF by MASCC score. Patients with LRNF had an average length of stay of 3.3 days, compared with 6.2 days in our historical cohort. Sixteen patients (30%) were discharged within 24 hours. Only two patients with LRNF had a culture-proven infection, both Enterococcus urinary tract infections. Three patients required nonelective readmission. There were no deaths caused by NF.
CONCLUSION: This pilot study demonstrates that a formal algorithm for LRNF management combined with provider education can improve current inpatient standard of care and length of stay without an increase in morbidity.

Entities:  

Mesh:

Year:  2017        PMID: 28282274     DOI: 10.1200/JOP.2016.017277

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  2 in total

1.  The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; J Virizuela Echaburu; M Sánchez Cánovas; F Ayala de la Peña
Journal:  Clin Transl Oncol       Date:  2017-03-13       Impact factor: 3.405

2.  Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.

Authors:  Prarthna V Bhardwaj; Megan Emmich; Alexander Knee; Fatima Ali; Ritika Walia; Prithwijit Roychowdhury; Jackson Clark; Arthi Sridhar; Tara Lagu; Kah Poh Loh
Journal:  Support Care Cancer       Date:  2021-03-24       Impact factor: 3.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.